EMI 200

Drug Profile

EMI 200

Alternative Names: EMI-200

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Edinburgh Molecular Imaging
  • Class Diagnostic agents; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lung disorders; Pneumonia

Most Recent Events

  • 24 Feb 2017 Preclinical data released by Edinburgh Molecular Imaging (Edinburgh Molecular Imaging website, February 2017)
  • 06 Apr 2016 Edinburgh Molecular Imaging plans a clinical trial in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top